TY - JOUR T1 - Genetic Analysis in Anal and Cervical Cancer: Exploratory Findings About Radioresistance in the ProfiLER Database JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 515 LP - 520 DO - 10.21873/cgp.20276 VL - 18 IS - 4 AU - ELISE ROWINSKI AU - NICOLAS MAGNE AU - WAFA BOULEFTOUR AU - PABLO MORENO-ACOSTA AU - CHRISTELLE DE LA FOURCHADIERE AU - ISABELLE RAY-COQUARD AU - QING WANG AU - JEAN-YVES BLAY AU - OLIVIER TREDAN Y1 - 2021/07/01 UR - http://cgp.iiarjournals.org/content/18/4/515.abstract N2 - Background/Aim: This study aimed to describe genomic alterations on squamous cell cervical and anal carcinomas. Materials and Methods: From 2013 to 2019, 3,269 patients were included in the molecular screening ProfiLER trial. Only patients with non-metastatic cervical or anal cancer, and those initially treated with radiotherapy in a curative intent were selected. Genetic analyses were performed by next generation sequencing (NGS). Results: Genomic alterations were observed in most patients: 5 patients out of 15 (33.3%) had at least one mutation on NGS and 4 out of 15 (26.7%) had at least one aberration of the number of copies of genes in the comparative genomic hybridation (CGH) analysis. The most common mutated gene was PIK3CA. Conclusion: All omic approaches must be integrated in the locally advanced cancer setting by new clinical trial design to develop two routes in the treatment strategy: intensification or de-escalation treatment strategy according to omic markers. ER -